JUVISÉ-PHARMACEUTICALS
4.2.2020 10:32:09 CET | Business Wire | Press release
The French specialty pharmaceutical company, Juvisé Pharmaceuticals is pleased to announce its successful syndication of its EUR 213 million debt package supporting the acquisition of Arimidex® and Casodex® from AstraZeneca, with the collaboration of Société Générale and HSBC, acting as Physical Bookrunners and Mandated Lead Arrangers, BNP Paribas, acting as Mandated Lead Arranger and Lazard acting as financial advisor to Juvisé Pharmaceuticals.
On the back of a strong support from both relationship lenders and institutional investors, syndication was wrapped following a successful and oversubscribed early-bird phase. The covenanted financing is comprised of a EUR 128 million TLB alongside a EUR 85 million TLA. This syndication was made possible through the collaboration with Juvisé Pharmaceuticals financial partners, with whom the company relies on long-term partnership characterized by openness and trust.
This successful syndication is another important step in Juvisé Pharmaceuticals development. It reasserts the company ability to leverage all debt capital instruments to fulfil its growth ambition, while keeping the flexibility and independence in decision making allowed by its privately held structure.
Frédéric Mascha, Founder and President of Juvisé Pharmaceuticals, declared, “We are very pleased that our acquisition debt package was successfully syndicated in this oversubscribed early-bird phase and we would like to thank our financial partners for the trust they have shown in our project. We are proud to see that our commitment towards physicians, patients, and our Pharma partners convinced renowned financial institutions to support our ambitious development plan.”
About Arimidex®
and Casodex®
Arimidex®
(anastrozole
) and Casodex®
(bicalutamide
) are hormone treatments for breast and prostate cancer. The two products are recognized as pillar in those cancer treatments and essential for both patients and physicians.
On 19th December 2019, Juvisé Pharmaceuticals acquired the rights of Arimidex® and Casodex® in 45 countries in Europe and a number of Middle Eastern and African markets.
About Juvisé Pharmaceuticals
Founded in 2008, Juvisé Pharmaceuticals is specialised in manufacturing, distributing and marketing its own branded pharmaceutical products. Juvisé focuses in offering treatments in: (i) Cardiology, (ii) Neuro-Psychiatry and (iii) Oncology.
The company business model consists in acquiring branded assets from large pharmaceutical companies like Novartis, AstraZeneca or Sigma Tau and optimising value creation through maximization of product life cycle.
11 years after its creation, Juvisé Pharmaceuticals has become a recognized international company commercializing its own treatments in 75 countries around the world.
For more information, please visit juvisepharmaceuticals.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005424/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verdict Expected Soon in Klarna’s $8.3 Billion Antitrust Lawsuit Against Google24.2.2026 19:09:00 CET | Press release
PriceRunner v. Google: Sweden’s Largest-Ever Civil Damages Claim Reaches Decision Stage; Klarna Provides Investor Update Klarna Group plc (NYSE: KLAR) announces that the Patent and Market Court of Sweden (Patent- och marknadsdomstolen) is expected to deliver its verdict on April 15, 2026 in the antitrust damages proceedings brought by Klarna’s subsidiary PriceRunner International AB against Google LLC and Google Ireland Limited. The trial, which ran from October 20 to December 19, 2025, concerned PriceRunner’s claim for approximately $8.3 billion in damages — the largest civil damages claim ever filed in a Swedish court. The Case The claim arises from Google’s abuse of dominance in online comparison shopping, as established by the European Commission in a binding 2017 decision and upheld without reservation by the Court of Justice of the European Union in September 2024. PriceRunner alleges that Google systematically demoted competing price comparison services in its search results whi
INRIX Announces New Generation of AI Traffic Products: Helping to Improve Safety, Reduce Congestion, and Enhance Mobility Operations24.2.2026 16:49:00 CET | Press release
New generative AI capabilities, enhanced incident detection, and expanded customer deployments mark a major evolution of the INRIX Traffic product family INRIX, a global leader in transportation data and analytics, today announced a major expansion of its Trafficfamily of products, delivering innovativeAI-driven capabilities to help transportation agencies and logistics organizations move from reactive traffic management to proactive, safety-focused and efficient operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224267928/en/ INRIX introduces expanded automation, generative AI capabilities, enhanced incident detection, and continuous analytics. Over twenty years ago, INRIX commercialized the first system to use GPS data to create real-time traffic information. In 2019, INRIX launched AI Traffic – the world's first traffic platform to leverage deep learning models and AI to improve the quality and analysis globall
Check Point and ControlPlane Partner to Help Enterprises Securely Scale AI and Accelerate Agentic Innovation24.2.2026 15:30:00 CET | Press release
ControlPlane, a specialist AI Security and DevSecOps consultancy, and Check Point Software Technologies Ltd., a pioneer and global leader in cyber security solutions, today announced a strategic collaboration to help enterprises securely adopt Large Language Models (LLMs) and agentic AI systems at scale. The partnership delivers a comprehensive, regulator-ready security framework designed to reduce risk, protect sensitive data, and enable organizations to move confidently from AI experimentation to production deployment. By combining Check Point’s AI-native threat prevention platform with ControlPlane’s deep expertise in cloud native architectures and DevSecOps, enterprises can operationalize AI securely without slowing innovation. As organizations advance AI initiatives beyond pilots, they face a growing “AI readiness gap.” Emerging threats such as prompt injection, unauthorized access, data leakage, and model misuse introduce risks that traditional security controls were not built to
Clinilabs Establishes EU Headquarters in Basel, Strengthening European Clinical Operations Under New Regional Leadership24.2.2026 15:00:00 CET | Press release
Clinilabs, a leading specialty contract research organization (CRO) focused on central nervous system (CNS) drug and device development, today announced the expansion of its European operations, including the establishment of its European Union headquarters at Switzerland Innovation Park Basel Area, and the appointment of Dr. Anne-Marie Nagy as executive vice president and head of Clinilabs Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224669284/en/ Dr. Anne-Marie Nagy appointed as Executive Vice President and Head of Clinilabs Europe Switzerland Innovation Park Basel Area is part of Switzerland’s national innovation network and located within the Basel region’s globally recognized life sciences cluster, bringing together biopharma companies, research institutions, and clinical innovation leaders. “Europe is a critical pillar of Clinilabs’ long-term growth strategy,” said Gary K. Zammit, Ph.D., president and chie
Yubico Unveils “YubiNation Partners”: A New Era of Global Channel Partnership to Secure Digital Identities in the Age of AI24.2.2026 15:00:00 CET | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), a modern cybersecurity company and creator of the most secure passkeys, today announced the launch of YubiNation Partners, a new global Channel program designed to unite a community of security experts. In the face of growing AI-driven cyber threats, the program enables partners to become trusted advisors and cultivate a safer digital world for their customers, making identities private and secure. As the average cost of a corporate security breach climbs to $4.4 million*, with phishing remaining a primary attack vector, the industry can no longer rely on passwords alone. In fact, a 2026 Total Economic Impact study from Forrester Consulting commissioned by Yubico, found that by replacing traditional multi-factor authentication (MFA) and one-time passwords (OTP) with YubiKeys, customers achieved a 265% return on investment (ROI). This effectively eliminated phishing and credential-theft risks, reducing an organization’s risk exposure to breach costs fr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom